<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667992</url>
  </required_header>
  <id_info>
    <org_study_id>D5252C00008</org_study_id>
    <nct_id>NCT00667992</nct_id>
  </id_info>
  <brief_title>Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma</brief_title>
  <official_title>A Phase 3, Randomised, Open-label, Crossover Study to Compare HFA vs CFC pMDI Formulations of Budesonide on Methacholine Hyper-reactivity in Patients With Stable, Persistent, Mild to Moderate Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being carried out to see if budesonide with HFA is effective, safe and well
      tolerated compared with budesonide CFC. Budesonide HFA has been already given in other
      research studies, in both healthy volunteers and subjects with asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PC 20 Methacholine (Provocative Concentration of Methacholine Causing 20 % Fall in FEV1(Forced Expiratory Volume)</measure>
    <time_frame>Baseline and week 2</time_frame>
    <description>Provocative concentration of methacholine is that causing a 20% fall in FEV1. The methacholine challenge test entailed the patient inhaling from an aerosol containing doubling concentrations of methacholine over a period of 2 minutes until FEV1 had been reduced by 20%.
The ratio of Methacholine concentration measured at 2 weeks to that at Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Exploratory Flow (PEF)</measure>
    <time_frame>Baseline to week 2 recorded daily</time_frame>
    <description>Change in PEF at Week 2 from baseline, mean over all days in run-in and all dasy in treatment period, with baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Forced Expiratory Volume in 1 Second)</measure>
    <time_frame>Baseline to week 2</time_frame>
    <description>FEV1 change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEF 25-75 (Forced Expiratory Flow 25-75)</measure>
    <time_frame>Baseline and week 2</time_frame>
    <description>FEF 25-75- Forced expiratory flow over the middle one half of the FVC. The results are expressed as the change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eNO (Exhaled Nitrogen Oxide)</measure>
    <time_frame>baseline and week 2</time_frame>
    <description>eNO ratio of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Score Morning</measure>
    <time_frame>2 weeks</time_frame>
    <description>Asthma Symptom score recorded daily in the morning: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the morning is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Score Evening</measure>
    <time_frame>2 weeks</time_frame>
    <description>Asthma Symptom score recorded daily in the evening: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the evening is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Score Total</measure>
    <time_frame>2 weeks</time_frame>
    <description>Asthma Symptom score recoded daily, Total. Scale: 0 - 3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Morning</measure>
    <time_frame>2 weeks</time_frame>
    <description>The average of means for inhalations of rescue medication in the morning is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Evening</measure>
    <time_frame>2 weeks</time_frame>
    <description>The average of means for inhalations of rescue medication in the evening is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Total</measure>
    <time_frame>2 weeks</time_frame>
    <description>The average of means for inhalations of rescue medication in morning and evening combined over a 24 hour period is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Exploratory Flow (PEF) Morning</measure>
    <time_frame>2 weeks</time_frame>
    <description>Peak Exploratory Flow (PEF) recorded daily in the morning</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Budesonide Hydrofluoroalkane (HFA) 100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide HFA 400</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide Chlorofluorocarbon (CFC) 100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide CFC 400</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide HFA</intervention_name>
    <description>standard daily inhaled dose</description>
    <arm_group_label>Budesonide Hydrofluoroalkane (HFA) 100</arm_group_label>
    <arm_group_label>Budesonide HFA 400</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide CFC</intervention_name>
    <description>standard daily inhaled dose</description>
    <arm_group_label>Budesonide Chlorofluorocarbon (CFC) 100</arm_group_label>
    <arm_group_label>Budesonide CFC 400</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from stable, persistent, mild to moderate asthma as defined by
             Global Initiative for Asthma (GINA) Guidelines and for whom FEV1 &gt; 60 %

          -  ICS taking ≤ 1000 μg BDP per day, or equivalent

          -  Methacholine PC20 &lt; 4 mg/mL

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to budesonide or any other constituents of the
             budesonide HFA pMDI or budesonide CFC pMDI.

          -  Currently a smoker or who has ceased smoking within 6 months of Visit 1.

          -  Exacerbations of asthma requiring oral steroids, hospitalisation or change in asthma
             therapy in the previous three months.

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or bronchiectasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Lipworth, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asthma and Allergy Research Group Division of Medicine and Therapeutics Ninewells Hospital and Medical School University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>King of Prussia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perth</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <results_first_submitted>May 12, 2010</results_first_submitted>
  <results_first_submitted_qc>October 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2012</results_first_posted>
  <last_update_submitted>October 9, 2012</last_update_submitted>
  <last_update_submitted_qc>October 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma hyperreactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>144 were enrolled, 45 were excluded: 11 for eligibility not fulfilled, 8 with condition under investigation worsened, 8 for voluntary withdrawal, 17 with reasons not specified, and 1 lost to follow-up and 99 were randomised.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Budesonide Hydrofluoroalkane (HFA) First, Then Budesonide CFC</title>
          <description>Budesonide Hydrofluoroalkane (HFA), 100 mcg twice daily followed by Budesonide HFA 400 mcg twice daily First, Wash out, then Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily followed by Budesonide CFC 400 mcg twice daily.</description>
        </group>
        <group group_id="P2">
          <title>Budesonide Chlorofluorocarbon (CFC) First, Then Budesonide HFA</title>
          <description>Budesonide CFC, 100 mcg twice daily followed by Budesonide CFC 400 mcg twice daily First, Wash out, then Budesonide HFA 100 mcg twice daily followed by 400 mcg twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention 100 Mcg Twice Daily</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Condition Under Investigation Worsened</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention 400 Mcg Twice Daily</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition Under Investigation Worsened</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication not allowed taken</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Wash-out</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not within one doubling dilution</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to wash-out</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Intervention 100 Mcg Twice Daily</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Forth Intervention 400 Mcg Twice Daily</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Budesonide Hydrofluoroalkane (HFA) First, Then Budesonide CFC</title>
          <description>Budesonide Hydrofluoroalkane (HFA), 100 mcg twice daily followed by Budesonide HFA 400 mcg twice daily, First then Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily followed by Budesonide CFC 400 mcg twice daily.</description>
        </group>
        <group group_id="B2">
          <title>Budesonide Chlorofluorocarbon (CFC) First, Then Budesonide HFA</title>
          <description>Budesonide CFC, 100 mcg twice daily followed by Budesonide CFC 400 mcg twice daily First, then Budesonide HFA 100 mcg twice daily followed by 400 mcg twice daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0" lower_limit="19.0" upper_limit="65.0"/>
                    <measurement group_id="B2" value="39.5" lower_limit="18.0" upper_limit="64.0"/>
                    <measurement group_id="B3" value="39.75" lower_limit="18.0" upper_limit="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PC 20 Methacholine (Provocative Concentration of Methacholine Causing 20 % Fall in FEV1(Forced Expiratory Volume)</title>
        <description>Provocative concentration of methacholine is that causing a 20% fall in FEV1. The methacholine challenge test entailed the patient inhaling from an aerosol containing doubling concentrations of methacholine over a period of 2 minutes until FEV1 had been reduced by 20%.
The ratio of Methacholine concentration measured at 2 weeks to that at Baseline.</description>
        <time_frame>Baseline and week 2</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane (HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon(CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>PC 20 Methacholine (Provocative Concentration of Methacholine Causing 20 % Fall in FEV1(Forced Expiratory Volume)</title>
          <description>Provocative concentration of methacholine is that causing a 20% fall in FEV1. The methacholine challenge test entailed the patient inhaling from an aerosol containing doubling concentrations of methacholine over a period of 2 minutes until FEV1 had been reduced by 20%.
The ratio of Methacholine concentration measured at 2 weeks to that at Baseline.</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.546" lower_limit="1.343" upper_limit="1.780"/>
                    <measurement group_id="O2" value="2.163" lower_limit="1.877" upper_limit="2.494"/>
                    <measurement group_id="O3" value="1.673" lower_limit="1.449" upper_limit="1.928"/>
                    <measurement group_id="O4" value="2.079" lower_limit="1.801" upper_limit="2.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Exploratory Flow (PEF)</title>
        <description>Change in PEF at Week 2 from baseline, mean over all days in run-in and all dasy in treatment period, with baseline as covariate.</description>
        <time_frame>Baseline to week 2 recorded daily</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane (HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon(CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Exploratory Flow (PEF)</title>
          <description>Change in PEF at Week 2 from baseline, mean over all days in run-in and all dasy in treatment period, with baseline as covariate.</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Liters/minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="3.9" upper_limit="15.6"/>
                    <measurement group_id="O2" value="12.7" lower_limit="6.8" upper_limit="18.6"/>
                    <measurement group_id="O3" value="12.0" lower_limit="6.1" upper_limit="17.9"/>
                    <measurement group_id="O4" value="9.1" lower_limit="3.2" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Forced Expiratory Volume in 1 Second)</title>
        <description>FEV1 change from baseline</description>
        <time_frame>Baseline to week 2</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane(HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon (CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Forced Expiratory Volume in 1 Second)</title>
          <description>FEV1 change from baseline</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="0.05" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.07" upper_limit="0.13"/>
                    <measurement group_id="O3" value="0.10" lower_limit="0.07" upper_limit="0.13"/>
                    <measurement group_id="O4" value="0.11" lower_limit="0.08" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEF 25-75 (Forced Expiratory Flow 25-75)</title>
        <description>FEF 25-75- Forced expiratory flow over the middle one half of the FVC. The results are expressed as the change from baseline</description>
        <time_frame>Baseline and week 2</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane(HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon (CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>FEF 25-75 (Forced Expiratory Flow 25-75)</title>
          <description>FEF 25-75- Forced expiratory flow over the middle one half of the FVC. The results are expressed as the change from baseline</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Liters/seconds</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.005" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.08" upper_limit="0.20"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.09" upper_limit="0.21"/>
                    <measurement group_id="O4" value="0.20" lower_limit="0.13" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>eNO (Exhaled Nitrogen Oxide)</title>
        <description>eNO ratio of baseline</description>
        <time_frame>baseline and week 2</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane(HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon (CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>eNO (Exhaled Nitrogen Oxide)</title>
          <description>eNO ratio of baseline</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.62" upper_limit="0.70"/>
                    <measurement group_id="O2" value="0.57" lower_limit="0.53" upper_limit="0.60"/>
                    <measurement group_id="O3" value="0.66" lower_limit="0.63" upper_limit="0.70"/>
                    <measurement group_id="O4" value="0.59" lower_limit="0.55" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom Score Morning</title>
        <description>Asthma Symptom score recorded daily in the morning: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the morning is presented.</description>
        <time_frame>2 weeks</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane(HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon(CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom Score Morning</title>
          <description>Asthma Symptom score recorded daily in the morning: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the morning is presented.</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.34" upper_limit="0.44"/>
                    <measurement group_id="O2" value="0.29" lower_limit="0.24" upper_limit="0.34"/>
                    <measurement group_id="O3" value="0.39" lower_limit="0.34" upper_limit="0.44"/>
                    <measurement group_id="O4" value="0.30" lower_limit="0.25" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom Score Evening</title>
        <description>Asthma Symptom score recorded daily in the evening: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the evening is presented.</description>
        <time_frame>2 weeks</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane(HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon (CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom Score Evening</title>
          <description>Asthma Symptom score recorded daily in the evening: Scale: 0-3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily in the evening is presented.</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.43" upper_limit="0.52"/>
                    <measurement group_id="O2" value="0.32" lower_limit="0.27" upper_limit="0.38"/>
                    <measurement group_id="O3" value="0.46" lower_limit="0.41" upper_limit="0.50"/>
                    <measurement group_id="O4" value="0.36" lower_limit="0.31" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom Score Total</title>
        <description>Asthma Symptom score recoded daily, Total. Scale: 0 - 3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily is presented.</description>
        <time_frame>2 weeks</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane(HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon (CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom Score Total</title>
          <description>Asthma Symptom score recoded daily, Total. Scale: 0 - 3. 0 = None; no asthma symptoms. 1 = Mild symptoms; aware of asthma symptoms but easily tolerated. 2 = Moderate symptoms; asthma causing enough discomfort to cause problems with normal activities (or with sleep). 3 =Severe symptoms; unable to do normal activities. The average of means for values recorded daily is presented.</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.78" upper_limit="0.96"/>
                    <measurement group_id="O2" value="0.61" lower_limit="0.52" upper_limit="0.71"/>
                    <measurement group_id="O3" value="0.85" lower_limit="0.76" upper_limit="0.94"/>
                    <measurement group_id="O4" value="0.66" lower_limit="0.56" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Morning</title>
        <description>The average of means for inhalations of rescue medication in the morning is presented.</description>
        <time_frame>2 weeks</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane (HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon (CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Morning</title>
          <description>The average of means for inhalations of rescue medication in the morning is presented.</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Number of inhalations</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" lower_limit="0.60" upper_limit="0.82"/>
                    <measurement group_id="O2" value="0.45" lower_limit="0.34" upper_limit="0.56"/>
                    <measurement group_id="O3" value="0.62" lower_limit="0.51" upper_limit="0.73"/>
                    <measurement group_id="O4" value="0.50" lower_limit="0.39" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Evening</title>
        <description>The average of means for inhalations of rescue medication in the evening is presented.</description>
        <time_frame>2 weeks</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane(HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon (CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Evening</title>
          <description>The average of means for inhalations of rescue medication in the evening is presented.</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Number of inhalations</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.77" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.52" upper_limit="0.80"/>
                    <measurement group_id="O3" value="0.84" lower_limit="0.71" upper_limit="0.97"/>
                    <measurement group_id="O4" value="0.64" lower_limit="0.50" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Total</title>
        <description>The average of means for inhalations of rescue medication in morning and evening combined over a 24 hour period is presented.</description>
        <time_frame>2 weeks</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane (HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon(CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Total</title>
          <description>The average of means for inhalations of rescue medication in morning and evening combined over a 24 hour period is presented.</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Number of inhalations/24 hours</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit="1.35" upper_limit="1.80"/>
                    <measurement group_id="O2" value="1.10" lower_limit="0.86" upper_limit="1.33"/>
                    <measurement group_id="O3" value="1.39" lower_limit="1.16" upper_limit="1.62"/>
                    <measurement group_id="O4" value="1.05" lower_limit="0.81" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Exploratory Flow (PEF) Morning</title>
        <description>Peak Exploratory Flow (PEF) recorded daily in the morning</description>
        <time_frame>2 weeks</time_frame>
        <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Hydrofluoroalkane (HFA) 100</title>
            <description>Budesonide Hydrofluoroalkane(HFA) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Budesonide HFA 400</title>
            <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Budesonide Chlorofluorocarbon (CFC) 100</title>
            <description>Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Budesonide CFC 400</title>
            <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Exploratory Flow (PEF) Morning</title>
          <description>Peak Exploratory Flow (PEF) recorded daily in the morning</description>
          <population>Full analysis set (FAS). The FAS was defined as all randomised patients who contributed data from at least one period (ie data from both low and high dose of one inhaler).</population>
          <units>Liters/minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426" lower_limit="421" upper_limit="431"/>
                    <measurement group_id="O2" value="437" lower_limit="433" upper_limit="442"/>
                    <measurement group_id="O3" value="428" lower_limit="424" upper_limit="433"/>
                    <measurement group_id="O4" value="438" lower_limit="433" upper_limit="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Budesonide Hydrofluoroalkane (HFA) 100</title>
          <description>Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Budesonide HFA 400</title>
          <description>Budesonide HFA 400 mcg twice daily for 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>Budesonide Chlorofluorocarbon (CFC) 100</title>
          <description>Budesonide Chlorofluorocarbon (CFC) 100 mcg twice daily for 2 weeks</description>
        </group>
        <group group_id="E4">
          <title>Budesonide CFC 400</title>
          <description>Budesonide CFC 400 mcg twice daily for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRa 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

